Inovio Pharma (INO) Posts Narrower than Expected Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.16 +2.65%
EPS Growth %: +75.9%
Financial Fact:
License fee and milestone revenue: 2.33M
Today's EPS Names:
AEHR, VFS, CMTL, More
EPS Growth %: +75.9%
Financial Fact:
License fee and milestone revenue: 2.33M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Inovio Pharmaceuticals, Inc. (NYSE: INO) reported Q1 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $1.74 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Levi (LEVI) Tops Q3 EPS by 12c; raises guidance
- Lamb Weston (LW) Tops Q1 EPS by 15c ; Offers Guidance
- AXIL Brands (AXIL) Reports Q1 EPS of $0.05
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
